Literature DB >> 1552311

Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography.

H Karbe1, M Grond, M Huber, K Herholz, J Kessler, W D Heiss.   

Abstract

Regional cerebral glucose metabolism was studied in nine patients with progressive supranuclear palsy (PSP). (18F)-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) revealed general cerebral hypometabolism in all PSP patients in comparison with an age-matched reference group. When comparing the degree of regional metabolic deterioration, a consistent pattern of the most affected brain regions became obvious: the strongest significant alteration of cerebral glucose metabolism was observed in subcortical regions, e.g. in caudate nucleus, lentiform nucleus and upper mid-brain, which showed nerve cell loss in previous pathological studies. Less severe, but still significant hypometabolism was observed in frontal cortex. This pattern of hypometabolism was distinctly different from that typically seen in dementias of Alzheimer's type. The present data show that PET findings agree with histopathological studies: PSP is a primarily subcortical disease with secondary inactivation of cortical, especially of frontal brain regions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552311     DOI: 10.1007/bf00862982

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man.

Authors:  M Reivich; D Kuhl; A Wolf; J Greenberg; M Phelps; T Ido; V Casella; J Fowler; E Hoffman; A Alavi; P Som; L Sokoloff
Journal:  Circ Res       Date:  1979-01       Impact factor: 17.367

Review 3.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

4.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy.

Authors:  M Ruberg; F Javoy-Agid; E Hirsch; B Scatton; R LHeureux; J J Hauw; C Duyckaerts; F Gray; A Morel-Maroger; A Rascol
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

5.  Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.

Authors:  R D'Antona; J C Baron; Y Samson; M Serdaru; F Viader; Y Agid; J Cambier
Journal:  Brain       Date:  1985-09       Impact factor: 13.501

6.  Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease.

Authors:  D Rougemont; J C Baron; P Collard; P Bustany; D Comar; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

7.  MR imaging in progressive supranuclear palsy and Shy-Drager syndrome.

Authors:  M Savoiardo; L Strada; F Girotti; L D'Incerti; M Sberna; P Soliveri; L Balzarini
Journal:  J Comput Assist Tomogr       Date:  1989 Jul-Aug       Impact factor: 1.826

8.  The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  E R Maher; A J Lees
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

9.  Thin-section CT of midbrain abnormalities in progressive supranuclear palsy.

Authors:  E F Masucci; F T Borts; J G Smirniotopoulos; J F Kurtzke; D Schellinger
Journal:  AJNR Am J Neuroradiol       Date:  1985 Sep-Oct       Impact factor: 3.825

Review 10.  Progressive supranuclear palsy. Clinical and pharmacologic update.

Authors:  J Jankovic
Journal:  Neurol Clin       Date:  1984-08       Impact factor: 3.806

View more
  11 in total

1.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016) : Reply to Jean-Claude Baron Letter to Editor.

Authors:  Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

2.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Jean-Claude Baron
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-15       Impact factor: 9.236

Review 3.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

4.  Executive dysfunction in subcortical ischaemic vascular disease.

Authors:  J H Kramer; B R Reed; D Mungas; M W Weiner; H C Chui
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 5.  Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies.

Authors:  Hai Cun Shi; Jian Guo Zhong; Ping Lei Pan; Pei Rong Xiao; Yuan Shen; Li Juan Wu; Hua Liang Li; Yuan Ying Song; Gui Xiang He; Hong Ye Li
Journal:  Neurol Sci       Date:  2013-03-30       Impact factor: 3.307

6.  Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography.

Authors:  Madhavi Tripathi; Vijay Dhawan; Shichun Peng; Suman Kushwaha; Amit Batla; Abhinav Jaimini; Maria M D'Souza; Rajnish Sharma; Sanjiv Saw; Anupam Mondal
Journal:  Neuroradiology       Date:  2013-01-13       Impact factor: 2.804

7.  Allocortical neurofibrillary changes in progressive supranuclear palsy.

Authors:  H Braak; K Jellinger; E Braak; J Bohl
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy.

Authors:  A Martínez; E Dalfó; G Muntané; I Ferrer
Journal:  J Neural Transm (Vienna)       Date:  2007-08-21       Impact factor: 3.575

9.  Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.

Authors:  M Ghaemi; R Hilker; J Rudolf; J Sobesky; W-D Heiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

Review 10.  Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Authors:  Zuzana Walker; Federica Gandolfo; Stefania Orini; Valentina Garibotto; Federica Agosta; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Marina Boccardi; Daniele Altomare; Cristina Festari; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.